Anticardiolipin Antibodies in COVID-19 – Report of Three Cases

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is prone to thrombotic events with pathogenic mechanism that are still incompletely understood. Occurrence of antiphospholipid antibodies, especially anticardiolipin antibodies, was described in many viral infections...

Full description

Saved in:
Bibliographic Details
Published in:Medicina interna (1992) 2021-01, Vol.18 (1), p.59-67
Main Authors: Dima, Alina, Moroti, Ruxandra Valentina, Popescu, Daniela Nicoleta, Berza, Ioana, Pârvu, Delia Adriana, Dumitrescu, Bianca
Format: Article
Language:English
Subjects:
antiphospholipid syndrome
lupus coagulant inhibitor
pneumonia
SARS-CoV-2
thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is prone to thrombotic events with pathogenic mechanism that are still incompletely understood. Occurrence of antiphospholipid antibodies, especially anticardiolipin antibodies, was described in many viral infections and could be part of the chain in micro-thrombosis occurrence in COVID-19. We herein present three cases of COVID-19 patients without any known immune background. For two of the patients, the laboratory tests show neither inflammatory syndrome, nor elevated D-dimer. Even if pauci-symptomatic patients, pulmonary involvement in as much as 10 - 25% was identified on chest computer tomography exam. In addition, a third patient, with more important pulmonary involvement (25-50%), inflammatory response and elevated D-dimer levels is presented. None of the patients had prolonged activated partial-thromboplastin time. IgM and/ or IgG anticardiolipin antibodies were found positives in all three cases.
ISSN:1220-5818
1220-5818
DOI:10.2478/inmed-2021-0151